Company Description
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States.
The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease.
In addition, the company’s preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease.
The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.
Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2019 |
| IPO Date | Sep 15, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 110 |
| CEO | Henry Gosebruch |
Contact Details
Address: 490 Arsenal Way, Suite 200 Watertown, Massachusetts 02472 United States | |
| Phone | 857 760 0900 |
| Website | neumoratx.com |
Stock Details
| Ticker Symbol | NMRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001885522 |
| CUSIP Number | 640979100 |
| ISIN Number | US6409791000 |
| Employer ID | 84-4367680 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jason G. Duncan J.D. | Chief Legal Officer |
| Dr. Robert Lenz M.D., Ph.D. | Head of Research and Development |
| Dr. Joshua Pinto Ph.D. | President |
| Michael Lee Milligan | Chief Financial Officer and Principal Accounting Officer |
| Dr. Daljit Singh Aurora Pharm.D. | Chief Operationg and development officer |
| Dr. Rajesh Manchanda Ph.D. | Chief Technical Operations Officer |
| Dr. Nicholas Brandon Ph.D. | Chief Scientific Officer |
| Helen Rubinstein | Head of Investor Relations |
| Amy Sullivan | Chief Human Resources Officer |
| Lori Houle | Chief Quality Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 11, 2025 | 8-K/A | [Amend] Current report |
| Mar 26, 2025 | EFFECT | Notice of Effectiveness |
| Mar 12, 2025 | 144 | Filing |
| Mar 3, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 3, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 3, 2025 | 10-K | Annual Report |
| Mar 3, 2025 | POSASR | Filing |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 21, 2025 | 8-K/A | [Amend] Current report |